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2007 cohort. The median time to biopsy post-HCT was 72
days (IQR 32-89) for the early cohort and 97 days (IQR 33-
119) for the more recent cohort, for an overall biopsy inci-
dence of 0.052 and 0.02 per 1000 patient days, respectively.
Patients in the 2003-2007 cohort were less likely to undergo
a lung biopsy (HR 0.52, CI 0.28-0.98, P¼ .04) when compared
to patients in the 1993-1997 cohort. Although a similar
number of patients underwent a bronchoscopy between the
two cohorts (272/1418 [19.2%] vs. 243/1148 [21.1%], P ¼ .22),
more patients in the early cohort underwent lung biopsy
without antecedent bronchoscopy (26/52 [50%] vs. 18/21
[86%], P ¼ .007). Infections were a more common ﬁnding at
biopsy in the early cohort (35/1418 vs. 8/1148, P < .001), but
the number of biopsies demonstrating non-infectious lesions
was similar between the two cohorts (17/1418 vs. 13/1148, P
¼ .85). Fungal infections were the major infectious etiology
in both cohorts (30/35[85%] vs. 5/8 [63%], P ¼ .15), but there
was a signiﬁcant reduction in the number of Aspergillus
species found at biopsy between the cohorts (29/52 vs. 1/21,
P < .001). A similar number of patients underwent biopsy
with a therapeutic intent in the two cohorts (8/52 [15%] vs. 3/
21 [14%]); all of those who underwent therapeutic biopsy in
the 2003-2007 cohort had documented Mucorales species.
Conclusions: Surgical evaluation of lung disease in HCT
recipients signiﬁcantly declined over a decade between
1993-1997 and 2003-2007. This decreased incidence of lung
biopsies between these two cohorts was related to a reduc-
tion in the number of biopsies for post-transplant infections,
particularly for those due to aspergillosis. We speculate that
this decline is related to the introduction of galactomannan
testing and the increased use of empiric therapy with
extended-spectrum azoles.298
Building Resiliency in New Nurses
Pamela Copass. Bone Marrow Tranpslantation and
Immunology, Cincinnati Children's Hospital Medical Center,
Cincinnati, OH
Background: The BoneMarrow Transplant Unit of Cincinnati
Children's Hospital Medical Center is a crucial care and
stressful unit. The nurses not only care for complex patients
with an array of co-morbidities, but also therapeutically
support the family. This may lead to an increased workload
and increased stress levels on nurses, which can potentially
cause burnout and turnover. Resiliency training has been
shown to decrease stress levels and improve positive outlook
in stressful work environments (Pipe et al. 2012; Steinhart et
al. 2008; Burton et al. 2010; Sood et al. 2011). There is a gap in
the literature regarding speciﬁc interventions to help new
nurses cope with the stressors of a critical care environment.
Research Question Do newly hired nurses who receive
resiliency training in addition to standard orientation
improve nurse job satisfaction scores and decrease job
turnover? Purpose/Intervention The purpose of this project
is to improve the well-being and job satisfaction of the new
staff nurses on the Bone Marrow Transplant Unit at CCHMC.
Using principles founded in positive psychology, an educa-
tion program will be implemented into the orientation
schedule of newly hired nurses. Job satisfaction scores and
stress levels will be monitored before the educational
program and at 6 months and 1 year post. Data will be
collected to determine the efﬁcacy of the additional educa-
tion throughout the orientation period.299
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Background: The purpose of our study was to evaluate the
incidence and outcome of Invasive Fungal Infections (IFI)
among patients who underwent autologous or allogeneic
Hematopoietic Stem Cell Transplantation (HSCT) at our BMT-
Unit.
Methods: This cohort-retrospective study,conducted during
02/1994 to 09/2012, involved HSCT patients admitted to our
BMT-Unit, who developed IFI.The IFI were classiﬁed accord-
ing to the modiﬁed EORTC/MSG criteria.
Results: Among 369 patients who underwent HSCT(88
allogeneic HSCT recipients and 281 autologous HSCT recipi-
ents), IFI occurred in 38 patients (overall incidence 10,3 %). 34
episodes (9,2 % of all patients) were due to molds, and 4 (1 %)
were due to yeasts. 27 episodes (30,6 %) occurred among the
allogeneic HSCT recipients, and 11 (3,9%) occurred among the
autologous HSCT recipients (RR 7.83, 95%CI 3.92-16.21).
Etiological agents were Aspergillus (31 episodes), Candida
(3 episodes), Rhodotorula (1 episode), Fusarium (1 episode),
Scedosporium (1 episode), Zygomycosis (1 episode). The
incidence of Aspergillosis was 25 % and 3,2 % among allo-
geneic and autologous HSCT recipients respectively (RR 7.80,
95%CI 3.58-17.75). The incidence of Candidiasis was 2,2 % and
0,3% among allogeneic and autologous HSCT recipients
respectively (RR 6.38, 95% CI 0.45-177.57). The overall
mortality rate for IFI was 5,7% among allogeneic HSCT
recipients and 1 % among autologous recipients (RR 5.32,95%
CI 1.13-27.79), whereas the attributable mortality rate for IFI
registered in our population was 21% (18,5 % for allogeneic
HSCT recipients and 27,2 % for autologous HSCT recipients
(RR 0.67,95% CI 0.16-3.34). The attributable mortality rate for
aspergillosis was 22,6 % (18,2 % and 33,3 % for allogeneic and
autologous HSCT recipients, respectively, RR 0.54,95%CI 0.12-
2.81), and the rate for Candida IFI was 0 %.
Conclusions: IFI represents a common complication for
allogeneic HSCT recipients.Aspergillosis is the most
frequently detected IFI in these patients. Conversely, autol-
ogous HSCT recipients rarely develop aspergillosis. Candi-
demiawas observed less often than aspergillosis among both
allogeneic and autologous HSCT recipients.
300
A Single Daily Ultra Low-Dose of Oral Acyclovir Is
Sufﬁcient to Prevent the Occurrence of Herpes Zoster
Post Hematopoietic Stem Cell Transplantation: Interim
Results of a Prospective Randomized Trial
David Dennison 1, Iman Maktoom Al Manthari 2,
Murtadha Al-Khabori 1, Revathi Raj 3, Sharat Damodar 4,
Alok Srivastava 5, Khalil Al Farsi 1, Mohammed Al Huneini 1,
Abdulhakeem Rawas 6, Yusra Al Habsi 2, Arwa Z. Al Riyami 1,
Aqeela Al Lawati 7, Intisar Al Riyami 7, Abdulla Balkhair 8,
Zahra Al Harthy 2, Shyam Sundar Ganguly 9, Salam Al Kindi 1.
1Hematology, Sultan Qaboos University Hospital, Muscat,
Oman; 2Nursing, Sultan Qaboos University Hospital, Muscat,
Oman; 3 Pediatric Hematology, Apollo Hopsitals, Chennai,
Chennai, Tamilnadu, India; 4 Hematology, Narayana
Hrudayalaya Hospital, Bangalore, India; 5 Department of
Haematology, Christian Medical College, Vellore, India;
Abstracts / Biol Blood Marrow Transplant 19 (2013) S257eS278S2626 Pediatrics, Sultan Qaboos University Hospital, Muscat, Oman;
7 Pharmacy, Sultan Qaboos University Hospital, Muscat, Oman;
8 Internal Medicine (ID), Sultan Qaboos University Hospital,
Muscat, Oman; 9 Biostatistics, Sultan Qaboos Unversity,
Muscat, Oman
Prophylactic acyclovir has been shown to decrease the risk of
varicella zoster virus (VZV) reactivation following hemato-
poietic stem transplantation (HSCT). In order to improve
compliance and to minimize potential toxicity, we investi-
gated the role of a single daily ultra low-dose of acyclovir in
preventing the occurrence of herpes zoster (HZ) following
HSCT. Between June 2008 till date, all HSCT patients in this
center are being randomized after informed consent, to
either receive low-dose acyclovir (LD Group) at 800mg twice
daily (20mg/kg twice daily if <40kg or ultra low-dose
acyclovir (uLD Group) at 200mg once daily (5mg/kg/day if
<40kg) for one year following HSCT. The primary endpoint of
this study is the occurrence of HZ at one year. For this interim
per-protocol analysis, a total of 80 consecutive patients with
a minimum of 6 months of follow up following cessation of
therapy were eligible for analysis. There were 40 patients in
each group. Both groups were comparable for age, median 11
yrs (0.3-53) in the LD group vs 13 yrs (0.5-43) in the uLD
group, underlying disease, type of transplant, graft versus
host disease and median time of randomization (33.4 vs 38
days post HSCT). None of the patients in the uLD group
developed HZ while on prophylaxis. One patient in the LD
group developed HZ (2.5%). This patient had a past history of
recurrent herpes zoster in the same dermatomal distribution
prior to HSCT while on therapy for acute leukemia. Five
patients developed HZ within 5 months after discontinuing
acyclovir (LD group ¼ 1, uLD group ¼ 4, P ¼ .358). Amongst
these patients the median time to develop HZ after stopping
prophylaxis was 31 days (9-142 days). This prospective
randomized study shows that a single daily ultra low-dose of
acyclovir given for one year following HSCT is sufﬁcient to
prevent HZ during a time when the patient is most vulner-
able to the consequences of VZV reactivation. Prolongation of
prophylaxis beyond a year may be necessary for patients
who continue to be severely immunosuppressed.301
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Background: We have previously demonstrated the safety/
efﬁcacy of prophylactic liposomal amphotericin B (L-AMB) in
preventing IFI for 100 days in pediatric allogenic stem cell
transplant (AlloSCT) recipients (Roman/Cairo et al PBC,
2008). Prophylaxis with L-AMB 3 mg/kg/day (Day 0 to +44)
and micafungin (Day +45 to +100) has been shown by our
group to be both safe and effective in preventing IFI (Small/
Cairo et al ASBMT, 2011).
Methods: Pediatric AlloSCT recipients received low dose L-
AMB at 1.5 mg/kg IV daily (Day 0 to +44), followed by
micafungin 1.5 mg/kg (max 50 mg) (Day +45 to +100). Allpatients received Tacrolimus and MMF for acute GVHD
prophylaxis as we previously described Bhatia / Cairo, BBMT,
2010. Plasma galactomannan and beta-glucan assays were
monitored BIW. Treatment success was deﬁned as preven-
tion of IFI by day 100.
Results: 23 patients (8 ALL, 2 AML, 3 TNHL, 1 HL, 1 DLBCL, 2
SAA, 1 FA, 1 SCD, 2 CGD, 1 SCID, 1 HLH) Median age: 11.7 yrs
(1mo-23.5 yr) Sex: 3F, 20M Conditioning: 12 myeloablative,
11 reduced toxicity; 7 CB donors (6 -unrelated, 1-related), 2
related PBSC, 6 RBM , 7 URBM, and 1 RBM+CB. Median time
to myeloid and platelet engraftment was 17 and 32.5 days,
respectively. Chimerism ¼ 98-100% day +100. Absolute CD4
count day +100 was (29-439 cells/mL). Probability of Grade II-
IV aGVHD was 17% and cGVHD 4%. Probability of 1-yr OS was
87% (95% CI: 64.8-95.6). One patient, history of CGD, had IFI
Aspergillus spp on lung biopsy Day +49. Probability of IFI by
day 100 was 4% (95% CI 0-64.3). Grade 3-4 toxicities: renal
insufﬁciency with concomitant other nephrotoxins occurred
in 14 pts (60.8%), low K+ in 12 (52.1%), and low Mg++ in 5
(21.7%). L-AMB dosing was changed due to renal toxicity in
10 patients (decreased dose in 1, decreased frequency in 4,
changed to micafungin in 2, and held doses in 3). False
positive beta-glucan was observed in 8 and galactomannan
in 3 pts.
Conclusions: Low dose (1.5 mg/kg/day) L-AMB followed by
micafungin is as effective in preventing IFI as prior studied
higher doses (3 mg/kg/day). Future studies should focus on
reducing toxicity but maintaining efﬁcacy. Beta-glucan and
galactomannan assays may be associated with a high inci-
dence of false positive results in pediatric AlloSCT recipients
and should not be used alone in clinical decision making.302
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Background: In a large cancer center, the average in-patient
admission for Hematopoietic Stem Cell Transplant (HSCT)
patients ranges between three to ﬁve weeks based on the
type of transplant. HSCT patients may experience not only
physiological complications but also psychological,
emotional, and spiritual distress during hospitalization. A
number of HSCT patients are from out of state and may not
have adequate family support throughout the course of
hospitalization further aggravating patients’ level of distress.
Music Therapy is a complementary treatment that addresses
physical, emotional, cognitive, and social needs of individ-
uals. It was introduced to HSCT patients as a supportive
measure to assist in alleviating stressors experienced during
the hospital stay.
Purpose: A group of HSCT nurses wanted to evaluate the
patient perceived beneﬁts of music therapy on HSCT patients
during their hospitalization. A secondary aim of this project
was to explore the literature regarding music therapy, with
the potential for incorporating it as a standard of practice in
the care of HSCT patients.
Intervention: After conducting a review of literature on the
beneﬁts of music therapy on HSCT patients, HSCT nurses in
collaboration with Music Therapists promoted a regular
